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We describe a liquid-chromatographic assay for cyclosporine (CyA) and four of its metabolites in blood. The method is sensitive and specific for this drug and its metabolites. The use of flow programming shortens total chromatographic run time to 30 mm, resulting in acceptable separation of metabolites at a lower flow rate and yielding narrower peaks for CyA and the internal standard at the higher flow rate. CyA and metabolites Met 17 and Met 1 were measured in seven heart transplant patients who were undergoing chronic therapy with CyA in oral doses ranging from 3 to 13 mg/kg body wt per day. For the individual patients, the mean trough concentrations in blood of CyA, Met 17, and Met 1 ranged from 111 to 221, 159 to 334, and 361090 4ug/L,respectively. Met 8 and Met 21 were not observed in any of these patients' blood specimens.
AddItIonal Keyphrases: immunosuppressarits . chromatography, reversed-phase -flow-programming -heart transplant Cyclosporine (cyclosporinA, CyA) is a cyclic undecapeptide produced as a metabolite by a soil fungus, Tolypocladium inflatum Gams (1). It has been successfully used as an immunosuppressant in the field of organ transplantation (2) .A major difficulty in the clinical use of CyA is its dosedependent nephrotoxicity (3) (4) (5) .
CyA is extensively biotransformed in humans and animals. Seventeen metabolites of CyA are known, 13 of which have been isolated and identified (6, 7). The biotransformation pathways are similar in mice, rats, rabbits, dogs, and humans (7, 8) . All identified metabolites contain the intact cyclic oligopeptide structure of the parent drug. Structural modifications consist of mono-and dihydroxylation and Ndemethylation at various sites on the CyA molecule (7) (8) (9) .
In OmniSolv; EM Science, Cherry Hill, NJ 08034). Distilled water (Glenwood Inglewood, Minneapolis, MN 55405), methanol, and acetonitrile were filtered separately under reduced pressure through a preffiter and a 0.4-tm (pore size) polycarbonate ifiter (both from Nucleopore Corp., Pleasanton, CA 94566) to remove any particulate matter.
Materials and Methods

Clinical Pharmacokinetics
To prepare mobile phase, we used 235 g of acetonitrile, 127 g of methanol, and 539 g of distilled water. The premixed mobile phase was degassed on the liquid chroniatograph under reduced pressure at 40#{176}C.
Standard Solutions
Standard solution of GyA. CyA, 6.36 mg, was dissolved in methanol and the volume was made up to 100 niL. A working standard of 2.544 p.g/mL was prepared by further dilution of this stock solution.
Internal standard solution. CyC, 4.51 mg, was dissolved in methanol and the volume was made up to 100 mL. A working standard of 4.51 pg/mL was prepared by further dilution.
Standard solution of metabolites. Metabolites Met 1, Met 8, Met 17, and Met 21 were dissolved, as received, in 10 mL of methanol. The concentrations ranged from 25 to 1000 ng/ mL. Exact concentrations of these metabolites were determined by assuming the same molar absorptivity as that of CyA. Peak areas, determined by integration for the metabolites, were compared with those for known amounts of CyA, to calibrate the metabolite standard solutions.
Procedures
Sample preparation.
CyA and metabolites were extracted from the blood samples by the method of Sawchuk and Cartier (16), with modifications as described below. Table 1 lists the concentration ranges of CyA and metabolites in the standard curves. One milliliter of drug-free human whole blood was added to the standard-curve tubes, and 1-niL samples of patients' blood were added to the appropriate sample tubes. Each pipette was rinsed with 1 mL of distilled water and the rinse was added to the corresponding standard or sample tube. From this point on, all tubes were treated identically. To the standards and blood samples 11 mL of diethyl ether was added with an automated pipette (Repipet; Lab Industries, Berkeley, CA 94710). The centrifuge tubes were stoppered with ground-glass stoppers, placed horizontally on a mechanical shaker (Eberbach Corp., Ann Arbor, MI 48106), and shaken at 180 cyclesper minute for 15 miii. All tubes were centrifuged at 750 x g for 5 miii.
A 10-mL aliquot of the ether phase was transferred by pipette to a clean 35-mL centrifuge tube, evaporated (EvapoMix), and 1.0 mL of HC1 (25 mmol/L), 2.0 mL of methanol, and 7.0 mL of n-hexane were added. The standards and samples were shaken for 5 mm and centrifuged for 5 miii as before. The n-hexane layer was aspirated and discarded, and 7.0 mL of fresh n-hexane was added. The shaking, centrifuging, and aspirating of the hexane layer was repeated as described.
Finally, Standard curves for the metabolites were linear over the concentration range of 25 to 1000 ng/mL. Standard curves for CyA were linear over the range of 50 to 3000 ng/mL. The precision of the analytical procedure was established by dayto-day reproducibility of standard curves for CyA and metabolites, as shown in Table 1 . Standard curves for Met 8 and Met 21 were not prepared daily because these metabolites were not detected in the patients' blood samples. The retention times of CyA and metabolites were found to be extremely sensitive to the composition of mobile phase, and varied for different batches of mobile phase. To minimize this variability, we weighed each component of mobile phase. The average useful life-time of the CN column at 60#{176}C was 500 injections, after which the resolution of metabolites was poor, but CyA could still be quantified. We have measured (Table 2) concentrations of CyA and metabolites in the blood of heart-transplant recipients undergoing chronic therapy with oral doses of CyA ranging from 3 to 13 mg/kg of body weight per day. These patients also received various other medications including prednisone, azathioprune, piperacillin, co-trimoxazole, trimethoprim, tobramycin, and clotrimazole. For the analysis to determine the concentrations of CyA and metabolites, the blood samples were drawn under steady-state conditions just before dosing.
Profiles of blood concentration vs time for CyA and two metabolites for two patients (patients 1 and 2 in Table 2 ) are shown in Figure 2 . Met 17 and Met 1 were detected in blood samples, but Met 8 and Met 21 were not observed in any of the seven patients monitored. Met 17 was present in all samples; however, Met 1 was detected in all samples from only five of the seven patients. In the other two patients, Met 1 was detected only in a few samples. These two patients had liver dysfunction, and one of them also had renal failure. In patient 1, the concentrations of Met 17 in blood were higher than the CyA concentrations in most of the samples ( Figure 2A) ; in patient 2 they were considerably higher than those of the parent drug ( Figure 2B ). Both were being treated chronically with oral CyA. That the latter patient had liver dysfunction was indicated by increased concentrations of bilirubin, alkaline phosphatase, aspartate aminotransferase, and lactate dehydrogenase in serum.
Discussion
CyA is monitored in transplant patients by using radioimmunoassay or HPLC because the drug's dose-related nephrotoxicity can be prevented by lowering the dose. Radioimmunoassay overestimates CyA by also quantiiring the cross-reacting metabolites.
In spite of its deficiencies, however, radioimmunoassay is commonly used to monitor concentrations of CyA in patients (17, 18).
CyA is slowly but extensively metabolized by the liver. Metabolism of CyA is catalyzed by the hepatic cytochrome P-450 monooxygenase system, resulting in hydroxylated and N-demethylated derivatives (7) (8) (9) . Cytochrome P-450 inducers such as rifampicin, phenytoin, phenobarbital, and Aroclor 1254 accelerate biotransformation of CyA (19). On the other hand, the cytochrome P450 inhibitor ketoconazole produces an increase in CyA concentrations, which may lead to nephrotoxicity (7,20-22) .
In animal studies, CyA administration has resulted in impaired hepatic drug metabolism (23) (24) (25) . During the administration of CyA (25 mg/kg per day) for 49 days to Sprague-Dawley rats, the activity concentrations of cytochrome P450 did not change, whereas aminopyrune Ndimethylase and NADPH-cytochrome c reductase activity Table 2 was decreased (23) . This decrease in monooxygenase enzyme activity resulted in a decrease in hepatic metabolism and increased CyA concentrations, which in turn led to nephrotoxicity (23) . Augustine and Zemaitis (25) reported impairment of cytochrome c reductase and, to a lesser extent, cytochrome P450 during the 50 mg/kg per day administration of CyA to Wistar rats. As a result of the decrease in N-deniethylation and aromatic hydroxylation drug-metabolizing reactions,these workers implied that CyA can impair its own metabolism, in which hydroxylated or N-demethylated derivatives, or both, are the primary metabolites. Such decreases in metabolic activity may lead to increased CyA/metabolite ratios, suggesting that measurement of metabolites may be useful clinically in this situation. Met 17 did not cause nephrotoxicity in spontaneously hypertensive rats (27) , and indirect evidence also suggests that these metabolites do not cause nephrotoxicity (28). Fabre et al. (29) have demonstrated that CyA is rapidly transformed in rabbit hepatocytes to various monohydroxylated, dihydroxylated, and dihydroxylated N-demethylated metabolites.
These metabolites, like CyA, have an affinity for intracellular binding components and are selectively retained for long periods inside the cells.
Metabolites Met 17 and Met 1 have been measured in the blood of renal-transplant (10) and heart-transplant patients (26) . Concentrations of Met 17 were found to be as much as four-to fivefold those of the parent compound in some hearttransplant patients during chronic therapy with CyA (26) .
Further studies are needed to confirm in vivo immunosup--pressive activity of these metabolites (10, 27) . The rate of metabolism of CyA is of importance in determining the A duration of action of the drug. Pharmacokinetic studies based on radioimmunoasaay may be difficult to interpret (30) because of the nonspecificity of the methodology. Assay of metabolites of CyA in transplant patients may provide insight into the role of these transformation products in immunosuppressive therapy.
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